TNXP

SEC filing TNXP Publishes TNX-1500 Phase 1 Data, Plans Kidney Transplant Study in H2 2026

6d ago

News Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket - Mainz Biomed ... - Benzinga

14d ago

SEC filing TNXP Announces TNX-4800 Bactericidal Antibody to Prevent Lyme Disease in US

18d ago

News Tonix Pharmaceuticals GAAP EPS of -$2.93 misses by $0.83, revenue of $6.9M misses by $0.05M

21d ago

News Tonix rises on commercial payer coverage for pain therapy

27d ago

SEC filing TNXP Secures Coverage for TONMYA, Providing Access to ~35M U.S. Commercial Lives, 20% of U.S. Commercial Market

27d ago

SEC filing TNXP Announces First Participant Dosed in Phase 1 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Migraine and Craniofacial Pain Treatment

68d ago

Insider trade Purchase by Seth Lederman (Chief Executive Officer)

75d ago

News Tonix Pharmaceuticals GAAP EPS of -$3.98 misses by $0.82, revenue of $5.39M beats by $2.42M

81d ago

SEC filing TNXP Launches TONMYA, FDA-Approved Fibromyalgia Drug, Posts $12M Revenue, +150% YoY Growth, NNT 7, NNH 26

84d ago

SEC filing TNXP Upgrades to Nasdaq Global Select Market from Nasdaq Capital Market Effective March 3, 2026

91d ago

News Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

153d ago

News Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

154d ago

News Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

155d ago

News Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

155d ago

Scanner Unusual volume (z=3.0)

160d ago

Scanner Unusual volume (z=2.9)

162d ago

Scanner Unusual volume (z=2.9)

163d ago

Scanner Unusual volume (z=2.9)

164d ago

SEC filing TNXP Licenses TNX-4900 Non-Opioid Pain Drug from Rutgers, Shows Promising Preclinical Results

168d ago